IMUNOR is an oral biotherapeutic drug that had been developed, registered, and approved in 1997 in the Czech Republic and Slovakia. IMUNOR is a dialyzable leukocyte extract (DLE) prepared from swine leukocytes. It is characterized as a mixture of small peptides with molecular weights smaller than 12 kDa and a specific portion of nucleotides. The medical uses of IMUNOR include therapeutic applications within its registered range of indications, primarily for the treatment of immunodeficiencies, allergies, and certain acute or relapsing bacterial infections in adults and children. Despite the long-term clinical application of DLE, with strong evidence of positive therapeutic effects and no serious side effects, a detailed physicochemical specification of this mixture was lacking. We developed several methods for more in-depth physicochemical characterization of IMUNOR, including a spectrophotometric method for quantification of the total protein concentration and total DNA concentration in a mixture, several chromatographic methods for identification of individual components present in significant concentrations in IMUNOR, such as HPLC methods and the Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis method, and characterization of amino acid composition of this mixture. For the investigation of the variability among different batches of IMUNOR, five to nine representative batches from a standard manufacturing process on an industrial scale were utilized. Using the analytical methods, we verified and confirmed the batch-to-batch reproducibility of the biological product IMUNOR.

BIOPHARM Research Institute of Biopharmacy and Veterinary Drugs Pohoří 90 254 01 Chotouň Czech Republic

Hameln rds s r o Horná 36 900 01 Modra Slovakia

ImunomedicA a s Chuderov118 400 02 Ústí nad Labem Czech Republic

See more in PubMed

Hofer M., Vacek A., Lojek A., Holá J., Štreitová D. Ultrafiltered Pig Leukocyte Extract (IMUNOR®) Decreases Nitric Oxide Formation and Hematopoiesis-Stimulating Cytokine Production in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages. Int. Immunopharmacol. 2007;7:1369–1374. doi: 10.1016/j.intimp.2007.06.003. PubMed DOI

Kirkpatrick C.H. Transfer Factors: Identification of Conserved Sequences in Transfer Factor Molecules. Mol. Med. 2000;6:332–341. doi: 10.1007/BF03401941. PubMed DOI PMC

Berrón-Pérez R., Chávez-Sánchez R., Estrada-García I., Espinosa-Padilla S., Serrano-Miranda E., Ondarza-Aguilera R., Pérez-Tapia M., Olvera B.P., Cano L., Pacheco P.U., et al. Indications, Usage, and Dosage of the Transfer Factor. Rev. Alerg. México. 2007;54:134–139. PubMed

Pérez-Tapia S.M., Pavón L., Vallejo-Castillo L., López-Morales C.A., Mellado-Sánchez G., Nieto-Patlán A., Velasco-Velázquez M.A., Medina-Rivero E., Estrada-Parra S. Transferon® en el 2020. Rev. Bio Cienc. 2020;7:10. doi: 10.15741/revbio.07.e901. DOI

Medina-Rivero E., Merchand-Reyes G., Pavón L., Vázquez-Leyva S., Pérez-Sánchez G., Salinas-Jazmín N., Estrada-Parra S., Velasco-Velázquez M., Pérez-Tapia S.M. Batch-to-Batch Reproducibility of TransferonTM. J. Pharm. Biomed. Anal. 2014;88:289–294. doi: 10.1016/j.jpba.2013.09.004. PubMed DOI

Salinas-Jazmín N., Estrada-Parra S., Becerril-García M.A., Limón-Flores A.Y., Vázquez-Leyva S., Medina-Rivero E., Pavón L., Velasco-Velázquez M.A., Pérez-Tapia S.M. Herpes Murine Model as a Biological Assay to Test Dialyzable Leukocyte Extracts Activity. J. Immunol. Res. 2015;2015:146305. doi: 10.1155/2015/146305. PubMed DOI PMC

Medina-Rivero E., Vallejo-Castillo L., Vázquez-Leyva S., Pérez-Sánchez G., Favari L., Velasco-Velázquez M., Estrada-Parra S., Pavón L., Pérez-Tapia S.M. Physicochemical Characteristics of TransferonTM Batches. BioMed Res. Int. 2016;2016:7935181. doi: 10.1155/2016/7935181. PubMed DOI PMC

Zajícová A., Javorková E., Trošan P., Chudíčková M., Krulová M., Holáň V. A Low-Molecular-Weight Dialysable Leukocyte Extract Selectively Enhances Development of CD4+RORγt+ T Cells and IL-17 Production. Folia Biol. 2014;60:253–260. doi: 10.14712/fb2014060060253. PubMed DOI

Cardoso F.M., Tomkova M., Petrovajova D., Bubanova M., Ragac O., Hornakova T. New and Cost Effective Cell-Based Assay for Dialyzed Leukocyte Extract (DLE)-Induced Jurkat Cells Proliferation under Azathioprine Treatment. J. Pharm. Biomed. Anal. 2017;138:100–108. doi: 10.1016/j.jpba.2017.01.052. PubMed DOI

Carballo-Uicab G., Linares-Trejo J.E., Mellado-Sánchez G., López-Morales C.A., Velasco-Velázquez M., Pavón L., Estrada-Parra S., Pérez-Tapia S.M., Medina-Rivero E. Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable Leukocyte Extract Intended for Batch Release. Molecules. 2019;24:3426. doi: 10.3390/molecules24193426. PubMed DOI PMC

Vallejo-Castillo L., Favari L., Vázquez-Leyva S., Mellado-Sánchez G., Macías-Palacios Z., López-Juárez L.E., Valencia-Flores L., Medina-Rivero E., Chacón-Salinas R., Pavón L., et al. Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point to Understand Its Mechanism of Action. Front. Pharmacol. 2020;11:569039. doi: 10.3389/fphar.2020.569039. PubMed DOI PMC

Zuniga-Navarrete F., Zavala-Meneses S.G., Zelnik V., Kopacek J., Skultety L. Initial Proteomic Characterization of IMMODIN, Commercially Available Dialysable Leukocytes Extract. Chem. Pap. 2021;75:1959–1968. doi: 10.1007/s11696-020-01467-w. DOI

Merchand-Reyes G., Pavón L., Pérez-Sánchez G., Vázquez-Leyva S., Salinas-Jazmín N., Velasco-Velázquez M., Medina-Rivero E., Pérez-Tapia S.M. Swine Dialyzable Spleen Extract as Antiviral Prophylaxis. J. Med. Food. 2015;18:1239–1246. doi: 10.1089/jmf.2014.0176. PubMed DOI

Oliveira C.R., Vieira R.P., de Oliveira Ferreira A., de Souza Schmidt Gonçalves A.E., Polonini H. Immunoregulatory Effects of Imuno TF® (Transfer Factors) on Th1/Th2/Th17/Treg Cytokines. bioRxiv. 2020 doi: 10.1101/2020.11.06.371435. DOI

Polonini H., Gonçalves A.E.D.S.S., Dijkers E., Ferreira A.D.O. Characterization and Safety Profile of Transfer Factors Peptides, a Nutritional Supplement for Immune System Regulation. Biomolecules. 2021;11:665. doi: 10.3390/biom11050665. PubMed DOI PMC

Molina M.A.F., Krímskaya S.E.S., Guerra R.T., Padilla C.R. A Review of IMMUNEPOTENT CRP, A Modifier of Biological Response: Efficacy and Current Practice. Biomed. J. Sci. Tech. Res. 2019;14:001–004. doi: 10.26717/BJSTR.2019.14.002509. DOI

Hromas J., Vacek A., Hofer M., Lukšíková E., Svoboda J., Schneiderová H. Hemopoiesis-Stimulating Effects and Enhanced Survival of Irradiated Mice after Peroral or Intraperitoneal Administration of Ultrafiltered Pig Leukocyte Extract (UPLE, IMUNOR®) Immunopharmacol. Immunotoxicol. 2002;24:651–664. doi: 10.1081/IPH-120016049. PubMed DOI

Arnaudov A. Immunotherapy with Dialyzable Leukocyte Extracts Containing Transfer Factor. In: Metodiev K., editor. Immunotherapy—Myths, Reality, Ideas, Future. InTech; London, UK: 2017.

Bílková A., Souček R., Vokrouhlický L. Transfer Faktor VUFB Lyofilizovany Roztok k Peroralní Aplikaci: Souhrnné Výsledky Klinickeho Hodnoceni. OKF VÚFB Praha. 1993;286

Gutová V., Hanzlíková J. IMUNOR v Lecbe Deti s Recidivujicimi Respiracnimi Infekty. Klin. Imunol. Alergol. 2004;14

Bystroň J., Petrů V., Kopecká K., Richterová I. Effects of the dialyzed pig leukocyte extract—IMUNOR on the clinical condition and basic laboratory parameters of immunity in patients with recurring or chronic infections. Alergie. 2007;9:61–66.

Pružinec P., Košturiak R., Kossárová K., Hochmuth L., Benedik R. The role of IMUNOR® in the management of patients with recurrent infections—The results of a multicenter observational study evaluating its clinical efficacy and safety in normal clinical practice. Alergie. 2018;20:245–254.

Bystroň J., Petrů V. The Effect of Oral Transfer Factor Administration on the Quality of Life of Children with Recurrent Respiratory Infections and Their Parents. Alergie. 2023;25:49–55.

Arnaudov A., Kostova Z. Dialysable Leukocyte Extracts in Immunotherapy. Biotechnol. Biotechnol. Equip. 2015;29:1017–1023. doi: 10.1080/13102818.2015.1060136. DOI

European Medicines Agency . Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products CPMP/ICH/365/96. European Medicines Agency; Amsterdam, The Netherlands: 1999.

Friendship R.M., Lumsden J.H., McMillan I., Wilson M.R. Hematology and Biochemistry Reference Values for Ontario Swine. Can. J. Comp. Med. 1984;48:390–393. PubMed PMC

Sipos W., Duvigneau C.J., Hartl R.T., Schwendenwein I. Exploratory Reference Intervals on Hematology and Cellular Immune System of Multiparous Large White Sows. Vet. Immunol. Immunopathol. 2011;141:307–311. doi: 10.1016/j.vetimm.2011.03.007. PubMed DOI PMC

Patterson J., Mura C. Rapid Colorimetric Assays to Qualitatively Distinguish RNA and DNA in Biomolecular Samples. J. Vis. Exp. JoVE. 2013;72:50225. doi: 10.3791/50225. PubMed DOI PMC

Hernández-Esquivel M.A., Pérez-Torres A., Romero-Romero L., Reyes-Matute A., Loaiza B., Mellado-Sánchez G., Pavón L., Medina-Rivero E., Pestell R.G., Pérez-Tapia S.M., et al. The Dialyzable Leukocyte Extract TransferonTM Inhibits Tumor Growth and Brain Metastasis in a Murine Model of Prostate Cancer. Biomed. Pharmacother. 2018;101:938–944. doi: 10.1016/j.biopha.2018.03.012. PubMed DOI

European Pharmacopoeia. 11th ed. Council of Europe; Strasbourg, France: 2022.

Summerfield A., Guzylack-Piriou L., Schaub A., Carrasco C.P., Tâche V., Charley B., McCullough K.C. Porcine Peripheral Blood Dendritic Cells and Natural Interferon-Producing Cells. Immunology. 2003;110:440–449. doi: 10.1111/j.1365-2567.2003.01755.x. PubMed DOI PMC

Lu Y. Pharmaceutical and Food Testing. Agilent Technologies, Inc.; Santa Clara, CA, USA: 2017. Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column. Application Note.